Abatacept (Orencia)

A fusion protein immunoconjugate of the extracellular domain of CTLA4 and the Fc domain of human IgG1. It functions as a T-cell co-stimulation blocker that inhibits TNF-ALPHA and prevents the activation of T-LYMPHOCYTES. It is used in the treatment of RHEUMATOID ARTHRITIS.

Also Known As:

Orencia; BMS 188667; BMS-188667; BMS-224818; BMS224818; Belatacept; CTLA-4-Ig; CTLA4-Fc; CTLA4-Ig; CTLA4-Ig Immunoconjugate; Cytotoxic T Lymphocyte-Associated Antigen 4-Immunoglobulin; LEA29Y; Nulojix; BMS 224818; BMS188667; CTLA4 Ig Immunoconjugate; Cytotoxic T Lymphocyte Associated Antigen 4 Immunoglobulin; Immunoconjugate, CTLA4-Ig

Networked: 1362 relevant articles (216 outcomes, 328 trials/studies)

Relationship Network

Drug Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Immunoconjugates: 3432
        Abatacept: 1362
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Immunoconjugates: 3432
        Abatacept: 1362

Experts

1.	Emery, Paul: 31 articles (01/2022 - 06/2002)
2.	Mariette, Xavier: 21 articles (08/2022 - 05/2009)
3.	Takeuchi, Tsutomu: 20 articles (04/2022 - 03/2013)
4.	Alten, Rieke: 19 articles (08/2022 - 06/2002)
5.	Schiff, Michael: 19 articles (04/2022 - 09/2005)
6.	Tanaka, Yoshiya: 17 articles (04/2022 - 01/2014)
7.	Kremer, Joel M: 17 articles (06/2021 - 06/2005)
8.	Curtis, Jeffrey R: 16 articles (01/2020 - 08/2011)
9.	Le Bars, Manuela: 16 articles (05/2019 - 08/2012)
10.	Westhovens, Rene: 16 articles (01/2018 - 06/2006)

Related Diseases

1.	Rheumatoid Arthritis 01/01/2015 - "More recently, evidence from the Assessing Very Early Rheumatoid arthritis Treatment (AVERT) trial showed that complete drug-free remission following treatment with abatacept may be a possibility in some patients with early RA, indicating that the disease course could be altered by early intervention. " 01/01/2022 - "Long-term good outcome of the fibrocavitary form of pulmonary Mycobacterium avium complex disease with concomitant abatacept monotherapy in a patient with rheumatoid arthritis." 01/01/2023 - "The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study." 01/01/2018 - "Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study." 11/01/2016 - "Differences in Predictive Factors for Sustained Clinical Remission with Abatacept Between Younger and Elderly Patients with Biologic-naive Rheumatoid Arthritis: Results from the ABROAD Study."
2.	Arthritis (Polyarthritis) 12/01/2011 - "A post-hoc analysis suggests however that abatacept may be beneficial in lupus patients with arthritis however, it will probably never be approved for that indication. " 06/01/2013 - "Abatacept is a biologic developed for inflammatory arthritis but has shown promise in SLE. " 07/15/2019 - "We present a study protocol for a multi-centre, randomised, double-blind, parallel-group, placebo-controlled trial that seeks to test the feasibility, acceptability and effectiveness of a 52-week period of treatment with the first-in-class co-stimulatory blocker abatacept for preventing or delaying the onset of inflammatory arthritis. " 07/15/2019 - "Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol." 01/01/2017 - "Abatacept reduces disease activity and ultrasound power Doppler in ACPA-negative undifferentiated arthritis: a proof-of-concept clinical and imaging study."
3.	Inflammation (Inflammations) 01/01/2023 - "Although, belatacept based immunosuppression may increase the risk of early acute cellular rejection, it may however be beneficial in stabilization of long-term renal function and improvement in inflammation in patients with chronic active antibody mediated rejection. " 01/01/2020 - "In seropositive, MTX-naive patients with early RA and presence of objectively measured high inflammation by MRI, indicating poor prognosis, remission rates were higher with abatacept plus MTX treatment versus MTX." 01/01/2020 - "In patients with low baseline MRI inflammation, remission rates were not significantly different with abatacept plus MTX versus MTX (SDAI: 39.7% versus 32.3%; P = 0.4961). " 01/01/2020 - "In patients with high baseline MRI inflammation, a significantly greater proportion achieved remission at 12 months with abatacept plus MTX versus MTX across SDAI (45.1% versus 16.3%; P = 0.0022), CDAI (47.1% versus 20.4%; P = 0.0065), and Boolean indices (39.2% versus 16.3%; P = 0.0156). " 05/01/2013 - "Here, we provide an overview of recent mechanistic studies of the action of CTLA-4-Ig on different cell types involved in mediating inflammation and joint damage in RA."
4.	Proteinuria 09/01/2020 - "With median follow-up of 12 months (IQR 6.38), only 15 patients (46.9%) showed response in proteinuria reduction, and 12 patients (43.8%) achieved remission with abatacept. " 05/01/2018 - "Recently, there have been several reports that abatacept can induce proteinuria remission in MCD and FSGS. " 11/01/2016 - "However, after this initial enthusiasm, several reports have not confirmed the efficiency of abatacept at inducing proteinuria remission in patients. " 08/01/2016 - "Indeed, in four patients with recurrent FSGS after transplant, treatment with the B7-1 blocker abatacept was associated with proteinuria remission. " 01/01/2023 - "Two patients with rFSGS without biopsies resolved proteinuria after abatacept. "
5.	Fatigue 02/01/2007 - "A significantly greater percentage of patients treated with abatacept reached normative levels of PCS, MCS, physical functioning, and fatigue compared with patients treated with MTX alone. " 07/01/2014 - "In this open-label study, abatacept treatment is effective, safe and well tolerated, and results in improved disease activity, laboratory parameters, fatigue and HR-QoL in patients with early and active pSS. " 06/01/2017 - "Of 1536 patients (mean disease duration: 6.2 months [AGREE], 8.5 years [AIM], 12.2 years [ATTAIN]), mean (SE) decreases in fatigue from baseline to day 169 with abatacept were 28.9 (1.7), 25.3 (1.2), and 21.9 (1.6) in AGREE, AIM, and ATTAIN, respectively, with corresponding decreases of 16.0, 13.7, and 13.4 at day 29. " 10/01/2010 - "Prespecified exploratory patient-reported outcomes (Short Form 36 health survey, sleep problems, fatigue) demonstrated a treatment effect with abatacept. " 11/01/2007 - "In both of these patient populations, treatment with abatacept was found to provide clinically meaningful health-related quality-of-life benefits, such as improvements in physical function, activity limitation, sleep, and fatigue. "

Related Drugs and Biologics

1.	Methotrexate (Mexate)
2.	tocilizumab (atlizumab)
3.	Abatacept (Orencia)
4.	Rituximab (Mabthera)
5.	Tumor Necrosis Factor Inhibitors
6.	Antirheumatic Agents (DMARD)
7.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
8.	Adalimumab (Humira)
9.	Infliximab (Remicade)
10.	Proteins (Proteins, Gene)

Related Therapies and Procedures

1.	Therapeutics
2.	Kidney Transplantation
3.	Immunotherapy
4.	Aftercare (After-Treatment)
5.	Drug Tapering